Last reviewed · How we verify
chiglitazar sodium tablets
chiglitazar sodium tablets is a PPAR agonist Small molecule drug developed by Chipscreen Biosciences, Ltd.. It is currently in Phase 2 development. Also known as: Bilessglu®, CS-038, Carfloglitazar.
Chiglitazar acts as a pan-PPAR agonist, activating all three PPAR subtypes (alpha, gamma, and delta) to regulate glucose and lipid metabolism.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | chiglitazar sodium tablets |
|---|---|
| Also known as | Bilessglu®, CS-038, Carfloglitazar |
| Sponsor | Chipscreen Biosciences, Ltd. |
| Drug class | PPAR agonist |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
Chiglitazar is a balanced pan-PPAR agonist that simultaneously activates PPAR-alpha, PPAR-gamma, and PPAR-delta receptors. This multi-target approach aims to improve insulin sensitivity, reduce blood glucose levels, and favorably modulate lipid profiles while potentially minimizing side effects associated with selective PPAR agonists.
Approved indications
Common side effects
Key clinical trials
- A Phase II Clinical Trial of Chiglitazar for NASH (PHASE2)
- Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chiglitazar sodium tablets CI brief — competitive landscape report
- chiglitazar sodium tablets updates RSS · CI watch RSS
- Chipscreen Biosciences, Ltd. portfolio CI
Frequently asked questions about chiglitazar sodium tablets
What is chiglitazar sodium tablets?
How does chiglitazar sodium tablets work?
Who makes chiglitazar sodium tablets?
Is chiglitazar sodium tablets also known as anything else?
What drug class is chiglitazar sodium tablets in?
What development phase is chiglitazar sodium tablets in?
Related
- Drug class: All PPAR agonist drugs
- Manufacturer: Chipscreen Biosciences, Ltd. — full pipeline
- Also known as: Bilessglu®, CS-038, Carfloglitazar
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing